Drug intelligence / Profile preview

Stillen

Development stage
Phase 4
Lead developer
Dong-A ST
Modality
Small Molecules
Administration
Oral
01

Overview

Stillen is a botanical pharmaceutical product developed by Dong-A ST, derived from the ethanol extract of *Artemisia asiatica* (Mugwort). It is primarily indicated for the treatment of gastric mucosal lesions, such as erosion, hemorrhage, redness, and edema, associated with acute and chronic gastritis, and for the prevention of gastric mucosal damage in patients taking non-steroidal anti-inflammatory drugs (NSAIDs). Stillen exerts its therapeutic effects through a multi-modal cytoprotective mechanism that includes the stimulation of endogenous prostaglandin E2 (PGE2) synthesis and the enhancement of gastric mucus secretion. Additionally, it possesses significant anti-inflammatory and antioxidant properties, mediated by the inhibition of nuclear factor kappa B (NF-κB) activation and the reduction of inflammatory cytokines like interleukin-8 (IL-8). As the first 'natural product drug' approved in South Korea, Stillen has established a significant clinical presence in the management of acid-related gastrointestinal disorders.

Brand names
StillenStillen 2XStillen2XStillen-2X
Other names
Artemisia asiatica ethanol extractMugwort extractDA9601DA-9601DA 9601
02

Targets

NF-κBPGE2 (Prostaglandin E2)

Beyond the preview

Go deeper on Stillen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stillen.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call